Eyenovia, which is developing micro-formulations of common eye therapies, raised $27 million by offering 2.7 million shares at $10, the low end of the range of $10 to $12. Eyenovia plans to list on the Nasdaq under the symbol EYEN. Ladenburg Thalmann and Roth Capital acted as lead managers on the deal.
